(Q33372516)

English

Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma (English)

1 reference

Europe PubMed Central

26 July 2017

mantle cell lymphoma

1 reference

based on heuristic

inferred from title

lymphoproliferative disorders

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Anna Szmigielska-Kaplon

object named as

Anna Szmigielska-Kaplon

4

0 references

1

object named as

Tadeusz Robak

1 reference

Europe PubMed Central

26 July 2017

Piotr Smolewski

2

object named as

Piotr Smolewski

1 reference

Europe PubMed Central

26 July 2017

Jerzy Z. Blonski

6

object named as

Jerzy Z Blonski

1 reference

Europe PubMed Central

26 July 2017

Barbara Cebula-Obrzut

3

object named as

Barbara Cebula

1 reference

Europe PubMed Central

26 July 2017

author name string

Krzysztof Chojnowski

5

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

1 October 2006

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

107

1 reference

Europe PubMed Central

26 July 2017

1542-1550

1 reference

Europe PubMed Central

26 July 2017

7

1 reference

Europe PubMed Central

26 July 2017

Intermittent infusion of cladribine (CdA) in previously treated patients with low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

21 January 2018

Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-CD20-based therapy of B cell lymphoma: state of the art.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

Monoclonal antibodies in the treatment of chronic lymphoid leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of cladribine combined with etoposide in heavily pretreated patients with indolent lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, Stage III or IV, low-grade non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of a phase II multicenter trial of pentostatin and rituximab in patients with low grade B-cell non-Hodgkin's lymphoma: an effective and minimally toxic regimen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22196

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.22196

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33372516&oldid=1913052197"